This article is one of four invited review articles published in the Raising Awareness of Hepatorenal Syndrome Acute Kidney Injury supplement, which includes CME-accredited articles published in Clinical Gastroenterology and Hepatology (CGH). The program is administered by AGA. Each article will provide expert perspectives on a topic related to practice gaps in the care and management of patients with Hepatorenal Syndrome Acute Kidney Injury. This program is commercially supported by Mallinckrodt.
Faculty:
Jasmohan S. Bajaj, MD, MS, FACG
Division of Gastroenterology, Hepatology, and Nutrition
Virginia Commonwealth University and Central Virginia Veterans Healthcare System
Nikki Duong, MD
Division of Gastroenterology, Hepatology, and Nutrition
Virginia Commonwealth University and Central Virginia Veterans Healthcare System,
Payal Kakadiya, PharmD
Division of Pharmacy; Virginia Commonwealth University Health
Learning Objectives:
- Identify the diagnostic criteria for Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI).
- Diagnose causes other than HRS when a patient with abnormal liver enzymes presents with AKI.
- Identify the recommended treatment of high-risk varices in patients with HRS-AKI.
- Demonstrate understanding of the contraindications to use of Terlipressin.
Released: July 31, 2023
Expires: Sept. 30, 2024
Disclosures
Jasmohan S. Bajaj: author for this educational activity his institution has received investigator initiated funding from Mallinckrodt Pharmaceuticals.
Nikki Duong: author for this educational activity has no relevant financial relationships with ineligible company to disclose.
Payal Kakadiya: author for this educational activity has no relevant financial relationships with ineligible company to disclose.
Charles J. Kahi, Editor-in-Chief, has no relevant financial relationship with ineligible company to disclose.
Swati Patel, Special Section Editor, for this educational activity has no relevant financial relationships with ineligible company to disclose.
Thoba Petrovic, AGA staff, has no relevant financial relationships with ineligible company to disclose.
Podcast
Interested in learning more or seeking additional CMEs?
Explore the related podcast series provided below:
Accreditation and designation statement
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AGA Institute designates this live activity for a maximum of 0.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME's Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners. The relevant financial relationships of those persons in a position to control the content of this CME activity will be disclosed prior to the start of the educational activity.
CME expiration date: Sept. 30, 2024
